vs
CytomX Therapeutics, Inc.（CTMX）与Ponce Financial Group, Inc.（PDLB）财务数据对比。点击上方公司名可切换其他公司
Ponce Financial Group, Inc.的季度营收约是CytomX Therapeutics, Inc.的1.7倍（$31.4M vs $18.7M），Ponce Financial Group, Inc.净利率更高（36.3% vs -0.8%，领先37.1%），Ponce Financial Group, Inc.同比增速更快（37.6% vs -25.7%），Ponce Financial Group, Inc.自由现金流更多（$54.6M vs $-15.8M），过去两年Ponce Financial Group, Inc.的营收复合增速更高（23.7% vs -15.9%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
庞塞金融集团是总部位于美国的金融控股公司，核心子公司为庞塞银行，主要服务纽约大都会区的多元文化、移民及中低收入社区，提供存款账户、按揭贷款、小微企业融资、个人信贷等零售及商业银行服务。
CTMX vs PDLB — 直观对比
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $31.4M |
| 净利润 | $-154.0K | $10.1M |
| 毛利率 | — | — |
| 营业利润率 | -6.9% | 43.6% |
| 净利率 | -0.8% | 36.3% |
| 营收同比 | -25.7% | 37.6% |
| 净利润同比 | 97.6% | 245.6% |
| 每股收益（稀释后） | — | $0.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | — | $31.4M | ||
| Q3 25 | — | $26.7M | ||
| Q2 25 | $18.7M | $26.5M | ||
| Q1 25 | $50.9M | $24.6M | ||
| Q4 24 | $38.1M | $22.8M | ||
| Q3 24 | $33.4M | $20.2M | ||
| Q2 24 | $25.1M | $20.2M | ||
| Q1 24 | $41.5M | $20.5M |
| Q4 25 | — | $10.1M | ||
| Q3 25 | — | $6.5M | ||
| Q2 25 | $-154.0K | $6.1M | ||
| Q1 25 | $23.5M | $6.0M | ||
| Q4 24 | $18.9M | $2.9M | ||
| Q3 24 | $5.7M | $2.4M | ||
| Q2 24 | $-6.5M | $3.2M | ||
| Q1 24 | $13.8M | $2.4M |
| Q4 25 | — | 43.6% | ||
| Q3 25 | — | 32.8% | ||
| Q2 25 | -6.9% | 30.2% | ||
| Q1 25 | 44.4% | 32.5% | ||
| Q4 24 | 46.4% | 19.6% | ||
| Q3 24 | 12.3% | 15.2% | ||
| Q2 24 | -33.7% | 21.8% | ||
| Q1 24 | 28.1% | 18.3% |
| Q4 25 | — | 36.3% | ||
| Q3 25 | — | 24.3% | ||
| Q2 25 | -0.8% | 23.0% | ||
| Q1 25 | 46.2% | 24.2% | ||
| Q4 24 | 49.6% | 14.1% | ||
| Q3 24 | 17.2% | 12.1% | ||
| Q2 24 | -26.0% | 15.8% | ||
| Q1 24 | 33.3% | 11.8% |
| Q4 25 | — | $0.43 | ||
| Q3 25 | — | $0.27 | ||
| Q2 25 | — | $0.25 | ||
| Q1 25 | — | $0.25 | ||
| Q4 24 | — | $0.11 | ||
| Q3 24 | — | $0.10 | ||
| Q2 24 | — | $0.14 | ||
| Q1 24 | — | $0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | $126.2M |
| 总债务越低越好 | — | $596.1M |
| 股东权益账面价值 | $119.9M | $541.5M |
| 总资产 | $175.1M | $3.2B |
| 负债/权益比越低杠杆越低 | — | 1.10× |
8季度趋势，按日历期对齐
| Q4 25 | — | $126.2M | ||
| Q3 25 | — | $146.6M | ||
| Q2 25 | $49.0M | $126.6M | ||
| Q1 25 | $47.6M | $129.9M | ||
| Q4 24 | $38.1M | $139.8M | ||
| Q3 24 | $40.6M | $155.8M | ||
| Q2 24 | $43.2M | $103.2M | ||
| Q1 24 | $36.2M | $134.7M |
| Q4 25 | — | $596.1M | ||
| Q3 25 | — | $521.1M | ||
| Q2 25 | — | $536.1M | ||
| Q1 25 | — | $521.1M | ||
| Q4 24 | — | $596.1M | ||
| Q3 24 | — | $580.4M | ||
| Q2 24 | — | $680.4M | ||
| Q1 24 | — | $680.4M |
| Q4 25 | — | $541.5M | ||
| Q3 25 | — | $529.8M | ||
| Q2 25 | $119.9M | $521.1M | ||
| Q1 25 | $25.0M | $513.9M | ||
| Q4 24 | $-456.0K | $505.5M | ||
| Q3 24 | $-23.5M | $504.6M | ||
| Q2 24 | $-31.2M | $497.7M | ||
| Q1 24 | $-31.7M | $493.7M |
| Q4 25 | — | $3.2B | ||
| Q3 25 | — | $3.2B | ||
| Q2 25 | $175.1M | $3.2B | ||
| Q1 25 | $98.5M | $3.1B | ||
| Q4 24 | $120.5M | $3.0B | ||
| Q3 24 | $139.0M | $3.0B | ||
| Q2 24 | $159.2M | $2.8B | ||
| Q1 24 | $184.7M | $2.8B |
| Q4 25 | — | 1.10× | ||
| Q3 25 | — | 0.98× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 1.01× | ||
| Q4 24 | — | 1.18× | ||
| Q3 24 | — | 1.15× | ||
| Q2 24 | — | 1.37× | ||
| Q1 24 | — | 1.38× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $55.6M |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | $54.6M |
| 自由现金流率自由现金流/营收 | -84.6% | 173.9% |
| 资本支出强度资本支出/营收 | 0.1% | 3.1% |
| 现金转化率经营现金流/净利润 | — | 5.48× |
| 过去12个月自由现金流最近4个季度 | $-77.7M | $74.3M |
8季度趋势，按日历期对齐
| Q4 25 | — | $55.6M | ||
| Q3 25 | — | $1.4M | ||
| Q2 25 | $-15.8M | $6.2M | ||
| Q1 25 | $-21.0M | $13.1M | ||
| Q4 24 | $-19.9M | $7.2M | ||
| Q3 24 | $-20.7M | $-14.6M | ||
| Q2 24 | $-19.5M | $-2.6M | ||
| Q1 24 | $-26.0M | $1.5M |
| Q4 25 | — | $54.6M | ||
| Q3 25 | — | $786.0K | ||
| Q2 25 | $-15.8M | $5.9M | ||
| Q1 25 | $-21.2M | $12.9M | ||
| Q4 24 | $-20.0M | $4.5M | ||
| Q3 24 | $-20.7M | $-15.0M | ||
| Q2 24 | $-19.6M | $-2.6M | ||
| Q1 24 | $-26.2M | $-315.0K |
| Q4 25 | — | 173.9% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | -84.6% | 22.4% | ||
| Q1 25 | -41.6% | 52.6% | ||
| Q4 24 | -52.5% | 19.7% | ||
| Q3 24 | -62.1% | -74.1% | ||
| Q2 24 | -78.2% | -13.0% | ||
| Q1 24 | -63.1% | -1.5% |
| Q4 25 | — | 3.1% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | 0.1% | 1.0% | ||
| Q1 25 | 0.2% | 0.6% | ||
| Q4 24 | 0.2% | 11.9% | ||
| Q3 24 | 0.1% | 2.0% | ||
| Q2 24 | 0.4% | 0.3% | ||
| Q1 24 | 0.3% | 8.7% |
| Q4 25 | — | 5.48× | ||
| Q3 25 | — | 0.21× | ||
| Q2 25 | — | 1.01× | ||
| Q1 25 | -0.89× | 2.20× | ||
| Q4 24 | -1.05× | 2.46× | ||
| Q3 24 | -3.61× | -5.99× | ||
| Q2 24 | — | -0.80× | ||
| Q1 24 | -1.89× | 0.61× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
PDLB
暂无分部数据
